perillaldehyde has been researched along with Cardiotoxicity in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hou, H; Li, P; Li, Z; Mi, S; Niu, Q; Que, H; Wang, H; Wang, Q; Yang, J; Yin, Y; Yu, Y; Zhan, H; Zhu, M | 1 |
1 other study(ies) available for perillaldehyde and Cardiotoxicity
| Article | Year |
|---|---|
PAE ameliorates doxorubicin-induced cardiotoxicity via suppressing NHE1 phosphorylation and stimulating PI3K/AKT phosphorylation.
Topics: Animals; Apoptosis; Cardiotoxicity; Doxorubicin; Myocytes, Cardiac; Oxidative Stress; Phosphatidylinositol 3-Kinases; Phosphorylation; Proto-Oncogene Proteins c-akt; Rats | 2022 |